{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:18:23Z","timestamp":1739423903416,"version":"3.37.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06153-5","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T04:15:13Z","timestamp":1734754513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report"],"prefix":"10.1007","author":[{"given":"Ayano","family":"Sugihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-1362","authenticated-orcid":false,"given":"Yasushi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Nagaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"1","key":"6153_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","volume":"19","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K (2014) Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 19(1):3\u20139. https:\/\/doi.org\/10.1007\/s10147-013-0641-7","journal-title":"Int J Clin Oncol"},{"issue":"24","key":"6153_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O\u2019Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531\u20132541. https:\/\/doi.org\/10.1056\/NEJMoa055229","journal-title":"N Engl J Med"},{"issue":"8","key":"6153_CR3","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, H\u00f6glund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K (2009) Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23(8):1398\u20131405. https:\/\/doi.org\/10.1038\/leu.2009.46","journal-title":"Leukemia"},{"issue":"12","key":"6153_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, B\u00f6hm A, Herndlhofer S, Tschachler E, Superti-Furga G, J\u00e4ger U, Valent P (2009) Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u00a0mg daily. Eur J Clin Invest 39(12):1098\u20131109. https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02206.x","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"6153_CR5","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.3324\/haematol.2019.217141","volume":"104","author":"J Yamaguchi","year":"2019","unstructured":"Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J (2019) Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia. Haematologica 104(8):e376\u2013e379. https:\/\/doi.org\/10.3324\/haematol.2019.217141","journal-title":"Haematologica"},{"issue":"7","key":"6153_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jiac.2021.01.009","volume":"27","author":"A Yamada","year":"2021","unstructured":"Yamada A, Katagiri S, Moriyama M, Asano M, Suguro T, Yoshizawa S, Akahane D, Tanaka Y, Furuya N, Fujimoto H, Gotoh M, Aota Y, Nakamura N, Gotoh A (2021) Epstein-Barr virus-associated post-transplant lymphoproliferative disease during dasatinib treatment occurred 10 years after umbilical cord blood transplantation. J Infect Chemother 27(7):1076\u20131079. https:\/\/doi.org\/10.1016\/j.jiac.2021.01.009","journal-title":"J Infect Chemother"},{"issue":"4","key":"6153_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/leu.2010.312","volume":"25","author":"MC B\u00e9n\u00e9","year":"2011","unstructured":"B\u00e9n\u00e9 MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, Maynadi\u00e9 M, Oelschlagel U, Orfao A, Schabath R, Solenthaler M, Tschurtschenthaler G, Vladareanu AM, Zini G, Faure GC, Porwit A (2011) Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 25(4):567\u2013574. https:\/\/doi.org\/10.1038\/leu.2010.312","journal-title":"Leukemia"},{"issue":"19","key":"6153_CR8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, Fo\u00e0 R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld A, Rousselot P, Ribera J, Bassan R (2024) Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 143(19):1891\u20131902. https:\/\/doi.org\/10.1182\/blood.2023020794","journal-title":"Blood"},{"key":"6153_CR9","doi-asserted-by":"publisher","unstructured":"Sugiura I, Doki N, Hata T, CHO R, Ito T, Suehiro Y, Kanamori H, Kako S, Matsuda M, Yokoyama H, Taniguchi Y, Hagihara M, Ozawa Y, Fujisawa S, Dobashi N, Hatta Y, Asada N, Ohashi K, Onishi Y, Shiro K, Nishiwaki S, Atsuta Y, Hayakawa F, Ohtake S, Miyazaki Y (2019) Dasatinib-based two-step induction prior to allogeneic hematopoietic cell transplantation for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the JALSGPh\u2009+\u2009ALL213 study. In: 61st ASH Annual Meeting and Exposition, Orlando, FL, vol Supplement 1. Blood, p 743. https:\/\/doi.org\/10.1182\/blood-2019-123382","DOI":"10.1182\/blood-2019-123382"},{"issue":"2","key":"6153_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","volume":"6","author":"I Sugiura","year":"2022","unstructured":"Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y (2022) Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv 6(2):624\u2013636. https:\/\/doi.org\/10.1182\/bloodadvances.2021004607","journal-title":"Blood Adv"},{"issue":"15","key":"6153_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/s1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O\u2019Brien S (2015) Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547\u20131555. https:\/\/doi.org\/10.1016\/s1470-2045(15)00207-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"6153_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajh.24653","volume":"92","author":"S Fujisawa","year":"2017","unstructured":"Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, Kakihana K, Dobashi N, Sugiura I, Onishi Y, Maeda T, Imai K, Ohtake S, Miyazaki Y, Ohnishi K, Matsuo K, Naoe T (2017) Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol 92(4):367\u2013374. https:\/\/doi.org\/10.1002\/ajh.24653","journal-title":"Am J Hematol"},{"issue":"1","key":"6153_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1128\/jcm.37.1.132-136.1999","volume":"37","author":"H Kimura","year":"1999","unstructured":"Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, Morishima T (1999) Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 37(1):132\u2013136. https:\/\/doi.org\/10.1128\/jcm.37.1.132-136.1999","journal-title":"J Clin Microbiol"},{"key":"6153_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","volume":"24","author":"E Baecklund","year":"2014","unstructured":"Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders\u2013what are the driving forces? Semin Cancer Biol 24:61\u201370. https:\/\/doi.org\/10.1016\/j.semcancer.2013.12.001","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"6153_CR15","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1182\/blood-2003-07-2436","volume":"102","author":"MW Bekkenk","year":"2003","unstructured":"Bekkenk MW, Vermeer MH, Meijer CJ, Jansen PM, Middeldorp JM, Stevens SJ, Willemze R (2003) EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 102(12):4243. https:\/\/doi.org\/10.1182\/blood-2003-07-2436","journal-title":"Blood"},{"issue":"10","key":"6153_CR16","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/sj.leu.2404758","volume":"21","author":"T Leguay","year":"2007","unstructured":"Leguay T, Foucaud C, Parrens M, Fitoussi O, Bouabdallah K, Belaud-Rotureau MA, Tabrizi R, Marit G, Pigneux A, Milpied N (2007) EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia. Leukemia 21(10):2208\u20132210. https:\/\/doi.org\/10.1038\/sj.leu.2404758","journal-title":"Leukemia"},{"issue":"1","key":"6153_CR17","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41598-020-61300-y","volume":"10","author":"R Kotaki","year":"2020","unstructured":"Kotaki R, Kawashima M, Yamamoto Y, Higuchi H, Nagashima E, Kurosaki N, Takamatsu M, Kikuti YY, Imadome KI, Nakamura N, Kotani A (2020) Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines. Sci Rep 10(1):4355. https:\/\/doi.org\/10.1038\/s41598-020-61300-y","journal-title":"Sci Rep"},{"issue":"4","key":"6153_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood.v98.4.972","volume":"98","author":"JW van Esser","year":"2001","unstructured":"van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Lowenberg B, Verdonck LF, Cornelissen JJ (2001) Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT. Blood 98(4):972\u2013978. https:\/\/doi.org\/10.1182\/blood.v98.4.972","journal-title":"Blood"},{"issue":"10","key":"6153_CR19","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","volume":"36","author":"F Fei","year":"2008","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Gotz M, Guillaume P, Dohner H, Bunjes D, Schmitt M (2008) Dasatinib exerts an immunosuppressive effect on CD8\u2009+\u2009T cells specific for viral and leukemia antigens. Exp Hematol 36(10):1297\u20131308. https:\/\/doi.org\/10.1016\/j.exphem.2008.05.002","journal-title":"Exp Hematol"},{"issue":"10","key":"6153_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/PAS.0000000000000488","volume":"39","author":"MG Ozawa","year":"2015","unstructured":"Ozawa MG, Ewalt MD, Gratzinger D (2015) Dasatinib-related Follicular Hyperplasia: an underrecognized entity with characteristic morphology. Am J Surg Pathol 39(10):1363\u20131369. https:\/\/doi.org\/10.1097\/PAS.0000000000000488","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"6153_CR21","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2013-07-513879","volume":"122","author":"C Roux","year":"2013","unstructured":"Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Cl\u00e9ment C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L (2013) Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase. Blood 122(17):3082\u20133084. https:\/\/doi.org\/10.1182\/blood-2013-07-513879","journal-title":"Blood"},{"issue":"11","key":"6153_CR22","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00277-017-3105-8","volume":"96","author":"A Iurlo","year":"2017","unstructured":"Iurlo A, Bucelli C, Cattaneo D, Orofino N, Giannotta JA, Zappa M, Gianelli U, Cortelezzi A (2017) Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia. Ann Hematol 96(11):1953\u20131954. https:\/\/doi.org\/10.1007\/s00277-017-3105-8","journal-title":"Ann Hematol"},{"key":"6153_CR23","doi-asserted-by":"publisher","unstructured":"Bouquet E, Jourdain A, Machet MC, Beau-Salinas F, Jonville-Bera AP (2017) Dasatinib-associated follicular lymphoid hyperplasia: first pediatric case report and literature review. Pediatr Blood Cancer 64(11). https:\/\/doi.org\/10.1002\/pbc.26597","DOI":"10.1002\/pbc.26597"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06153-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:09:17Z","timestamp":1739358557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06153-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":23,"alternative-id":["6153"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06153-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Shinya Kimura has received research funding from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceutical and Ohara Pharmaceuticals, and honoraria from Bristol-Myers Squibb, Novartis, Pfizer and Otsuka Pharmaceutical. Hiroshi Ureshino has received honoraria from Novartis. The remaining authors have stated that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}